Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

RSV antibody may cut wheezing hospitalizations in toddlers

NCT ID NCT07317141

First seen Jan 06, 2026 · Last updated May 21, 2026 · Updated 12 times

Summary

This study looks at whether giving nirsevimab, a shot that protects against RSV, to babies under 6 months old can reduce wheezing that leads to hospital visits when they are 1-2 years old. Researchers will compare 218,000 children in France who got the shot with those who did not, using health records. The goal is to see if early RSV prevention can lower the risk of asthma-like breathing problems later in childhood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA CHILDHOOD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospices Civils de Lyon - Hôpital Femme Mère Enfant

    Bron, 69677, France

Conditions

Explore the condition pages connected to this study.